Gian Marco Leggio - Concepedia

Author

Gian Marco Leggio

Also Known As

G M Leggio, G. M. Leggio, G.M. Leggio, Gian Leggio, Gian M. Leggio, Gian Marco Leggio, GianMarco Leggio, Leggio, Gian Marco

130

Publications

4.3K

Citations

H-Index

116

Concepts

All Affiliations

University of Catania Oasi Maria SS Istituti di Ricovero e Cura a Carattere Scientifico University of Modena and Reggio Emilia Italian Institute of Technology

About

Gian Marco Leggio is an author at University of Catania specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	42	2.1K
2	Social Sciences	17	18	675
3	Health Sciences	6	6	213
4	Engineering	3	3	233
5	Allergy	1	1	37

Gian Marco Leggio

Publications

Citations

H-Index

Page 1

	Year	Citations
Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels Vincenzo Micale, Luigia Cristino, Alessandra Tamburella, Neuropsychopharmacology Molecular PhysiologyBiochemistryFunctional SelectivityMedicineDual Blocker	2008	204
Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats Claudio Bucolo, Gian Marco Leggio, Filippo Drago, Biochemical Pharmacology Diabetic RetinopathyOcular DiseaseRetinaOphthalmologyExperimental Ophthalmology	2012	141
Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat Marialaura Amadio, Alessia Pascale, Sarha Cupri, Pharmacological Research NanomedicineOcular DiseaseEngineeringOphthalmologyNanobiotechnology	2016	111
The PKCβ/HuR/VEGF pathway in diabetic retinopathy Marialaura Amadio, Claudio Bucolo, Gian Marco Leggio, Biochemical Pharmacology Diabetic RetinopathyOcular DiseaseOphthalmologyDiabetesMedicine	2010	107
Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach Chiara Bianca Maria Platania, Luisa Di Paola, Gian Marco Leggio, Frontiers in Pharmacology	2015	83
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis Andrea Navarria, Alessandra Tamburella, Fabio Arturo Iannotti, Pharmacological Research Faah/trpv1 N-arachidonoylserotoninStress HormonePsychiatryBehavioral NeuroscienceStress	2014	81
Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1 Sebastiano Alfio Torrisi, Federica Geraci, Maria Rosaria Tropea, Frontiers in Pharmacology	2019	81
P2X7 receptor antagonism: Implications in diabetic retinopathy Chiara Bianca Maria Platania, Giovanni Giurdanella, Luisa Di Paola, Biochemical Pharmacology Molecular PharmacologyDiabetic RetinopathyOcular DiseaseOphthalmologyMedicine	2017	77
A New Human Blood–Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes Claudia G. Fresta, Annamaria Fidilio, Giuseppe Caruso, International Journal of Molecular Sciences	2020	77
Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway Francesca Lazzara, Annamaria Fidilio, Chiara Bianca Maria Platania, Biochemical Pharmacology InflammationOcular DiseaseSignal TransductionRetinaOphthalmology	2019	73

Page 1